A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06003829 |
Recruitment Status :
Completed
First Posted : August 22, 2023
Last Update Posted : October 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to learn about the tastes of different suspensions with the study medicine called PF-07923568 in healthy adult participants. In a suspension, the medicine is mixed with a liquid, usually water, in which it cannot dissolve and therefore remains intact in the form of small particles.
This study is seeking for healthy participants who:
- are aged 18 years of age or older.
- can produce a baby must agree to use a highly effective method of birth control.
- are confirmed to be healthy by some medical tests. This study can include both men and women.
- have body mass index (BMI) of 16 to 32 kg/m2 and a total body weight of more than 45 kilograms.
Participants will take sisunatovir prepared in 5 different suspensions and bitrex over two days to see if they are good to taste. Participants will answer a questionnaire after tasting each suspension. The questionnaire will be completed for each suspension. The questionnaire asks participants to test each suspension at 4 different times after tasting and spitting out the suspension. At least 60 minutes will pass between tasting each suspension.
The total planned time period of participation is around 5 to 8 weeks. This includes the screening period of up to 28 days. Followed by first administration of study medicine. Then a 3 day in-patient stay at the study clinic. It also includes a follow-up phone call that happens 28-35 days after the final taste test.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Sinsunatovir Other: Bitrex | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Other |
Official Title: | A RANDOMIZED, PHASE 1, SINGLE-BLIND, MULTI-PERIOD STUDY TO INVESTIGATE THE PALATABILITY OF PF-07923568 ORAL SUSPENSION IN DIFFERENT LIQUID VEHICLES IN HEALTHY ADULT PARTICIPANTS |
Actual Study Start Date : | July 31, 2023 |
Actual Primary Completion Date : | September 20, 2023 |
Actual Study Completion Date : | September 20, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment A |
Drug: Sinsunatovir
Single dose, to be spit out after tasting |
Experimental: Treatment B |
Drug: Sinsunatovir
Single dose, to be spit out after tasting |
Treatment C
Comparator
|
Other: Bitrex
Single dose, to be spit out after tasting |
Experimental: Treatment D |
Drug: Sinsunatovir
Single dose, to be spit out after tasting |
Experimental: Treatment E |
Drug: Sinsunatovir
Single dose, to be spit out after tasting |
Experimental: Treatment F |
Drug: Sinsunatovir
Single dose, to be spit out after tasting |
- Palatability Questionnaire - Mouth feel [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - Bitterness [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - Sweetness [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - Sourness [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - saltiness [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - tongue/mouth burn [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Palatability Questionnaire - overall liking [ Time Frame: 1, 5, 10, and 20 minutes after dose ]Evaluation with a validated color bar on a scale from 0 to 100. Outcomes will be summarized using descriptive statistics.
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) [ Time Frame: Baseline up to 35 days after last dose of study intervention ]
- Number of Participants With Clinical Laboratory Abnormalities [ Time Frame: Baseline up to Day 2 ]
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs [ Time Frame: Baseline up to Day 2 ]
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male and female participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, blood pressure, pulse rate and standard 12-lead electrocardiogram (ECG).
- Body mass index (BMI) of 16-32 kg/m2; and a total body weight >45 kg
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Conditions that affect ability to taste eg, dysgeusia, respiratory infection, cold, etc.
- History of hypersensitivity to the active compounds or to any inactive ingredients (excipients) contained in the formulations.
- Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.
- A positive urine drug test at screening or admission.
- A positive serum pregnancy test at screening and/or positive urine/serum pregnancy test in woman/women of childbearing potential (WOCBP) at Day -1
- Use of tobacco/nicotine containing products
- Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants <60 years; and ≥150/90 mm Hg for participants ≥60 years old, following at least 5 minutes of supine rest.
- Renal impairment as defined by an estimated glomerular filtration rate (eGFR) (units of mL/min/1.73m²) <60 mL/min(/1.73m²) based on 2021 chronic kidney disease epidemiology (CKD-EPI).
- Standard 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (Bili) ≥ 1.05 × upper limit of normal (ULN). Participants with an elevated total bilirubin consistent with Gilbert's Disease should have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06003829
Belgium | |
Pfizer Clinical Research Unit - Brussels | |
Brussels, Bruxelles-capitale, Région DE, Belgium, B-1070 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT06003829 |
Other Study ID Numbers: |
C5241014 2023-504924-24-00 ( Registry Identifier: CTIS (EU) ) |
First Posted: | August 22, 2023 Key Record Dates |
Last Update Posted: | October 31, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Denatonium Aversive Agents Molecular Mechanisms of Pharmacological Action Abuse-Deterrent Formulations |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |